Vectura Group plc Vectura to present at the J.P. Morgan Conference (7336T)
January 10 2017 - 1:00AM
UK Regulatory
TIDMVEC
RNS Number : 7336T
Vectura Group plc
10 January 2017
Vectura Group plc
Vectura to present at the 35th Annual J.P. Morgan Healthcare
Conference
Chippenham, UK - 10 January 2017: Vectura Group plc (LSE: VEC)
("Vectura") an industry-leading device and formulation business for
inhaled airways disease, today announces that James Ward-Lilley,
Vectura's CEO, is scheduled to present an overview of the business
at the 35th Annual J.P. Morgan Healthcare Conference in San
Francisco, on Wednesday, 11 January 2017, at 3:30pm PST (11:30pm
GMT).
A live webcast of the meeting and a copy of the presentation
slides will be available on Vectura's website:
http://www.vectura.com/investors/presentations-webcasts/. A
recording will be available following the presentation.
- Ends -
Enquiries
Vectura Group plc +44 (0)1249 667700
Andrew Derodra - Chief Financial Officer
Fleur Wood - Director Communications
Elizabeth Knowles - Director Investor Relations and Analysis
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange
(LSE: VEC), is an industry-leading inhaled airways disease focused
business with proprietary formulation and devices across DPI, pMDI
and "smart" nebulisation platforms. With our extensive range of
technologies, capabilities and collaborations, we believe we can
become a leader in the development of inhalation products,
increasing our ability to help patients suffering from respiratory
diseases. In June 2016 Vectura completed a merger with Skyepharma
PLC.
Vectura has seven inhaled, four non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a portfolio of drugs in clinical development, a number of which
have licence agreements with several global pharmaceutical and
biotechnology companies including Hikma, Novartis, Sandoz,
Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi,
Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at
www.vectura.com.
Forward-looking statements
This press release contains forward-looking statements,
including statements about the discovery, development and
commercialisation of products. Various risks may cause Vectura's
actual results to differ materially from those expressed or implied
by the forward-looking statements, including: adverse results in
clinical development programmes; failure to obtain patent
protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialise products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialisation
activities; and product initiatives by competitors. As a result of
these factors, prospective investors are cautioned not to rely on
any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLKLLBDFFLBBQ
(END) Dow Jones Newswires
January 10, 2017 02:00 ET (07:00 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024